Adherence to treatment of osteoporosis: a need for study
- First Online:
Adherence to anti-osteoporosis medications is currently low and is associated with poor anti-fracture efficacy. This manuscript reviews the potential design of clinical studies that aim to demonstrate improved adherence, with new chemical entities to be used in the management of osteoporosis.
Several medications have been unequivocally shown to decrease fracture rates in clinical trials. However, in real life settings, long-term persistence and compliance to anti-osteoporosis medication is poor, hence decreasing the clinical benefits for patients.
An extensive search of Medline from 1985 to 2006 retrieved all trials including the keywords osteoporosis, compliance, persistence or adherence followed by a critical appraisal of the data obtained through a consensus expert meeting.
The impact of non-adherence on the clinical development of interventions is reviewed, so that clinicians, regulatory agencies and reimbursement agencies might be better informed of the problem, in order to stimulate the necessary research to document adherence.
Adherence to therapy is a major problem in the treatment of osteoporosis. Both patients and medication factors are involved. Adherence studies are an important aspect of outcomes studies, but study methodologies are not well developed at the moment and should be improved. Performing adherence studies will be stimulated when registration authorities accept the result of these studies and include the relevant information in Sect. 5.1 of the summary of product characteristics. Reimbursement authorities might also consider such studies as important information for decisions on reimbursement.
KeywordsAdherence Compliance Persistence Registration Reimbursement
- 6.Silverman S, Siris E, Abbott T et al (2003) Adherence to bisphosphonate therapy is associated with decreased non-vertebral osteoporotic fracture risk. J Bone Miner Res 20 (suppl 1):S286Google Scholar
- 16.Mullen PD (1997) Compliance becomes concordance. B Med J 314:691–692Google Scholar
- 20.Fardellone P, Gaudin AF, Cotte FE (2005) Comparison of the persistence of daily and weekly bisphosphonates in female patients treated for osteoporosis. J Bone Miner Res 20 (Suppl 1):S285–S286Google Scholar
- 22.Docherty SM, Goodley A, Steel SA (2005) Compliance and effect of bone protective treatment in elderly females: 5 year follow-up study. Rheumatology 44(Suppl 1):134Google Scholar
- 24.Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 14:259–262Google Scholar
- 26.Briesacher BA, Andrade S, Kahler K et al (2006) Economic impact of the previous year’s adherence with bisphosphonates. J Bone Miner Res 21(suppl 1):S171Google Scholar
- 27.World Health Organization (2003) Adherence to long-term therapies: Evidence for action. WHO, Geneva, SwitzerlandGoogle Scholar
- 31.McCloskey E, de Takats D, Orgee J et al (2005) Characteristics associated with non-persistence during daily therapy. Experience from the placebo wing of a community-based clinical trial. J Bone Miner Res 20(suppl 1):S282Google Scholar
- 33.Thompson P, Cooper C, Carr A (2005) Factors influencing adherence to bisphosphonates for osteoporosis. J Bone Miner Res 20 (suppl):S394Google Scholar
- 36.Delmas PD, Vrijens B, Eastell R et al (2007) Improving measurements of persistence on actonel treatment (IMPACT) investigators. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:296–304CrossRefGoogle Scholar
- 38.Kanis JA et al (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256Google Scholar
- 39.Stevenson M, Davies S (2006) DSU economic evaluation of pooled alendronate and risedronate compared with strontium ranelate, raloxifene, etidronate and teriparatide http://guidance.nice.org.uk/page.aspx?o=370643)
- 40.Spilker B (1991) Methods of assessing and improving patient compliance in clinical trials. In: Cramer JA, Spilker B (eds) (1991) Patient compliance in medical practice and clinical trials. Raven press, New York pp 37–56Google Scholar
- 48.Pullar T, Feely M (1990) Problems of compliance with drug treatment: new solutions? Pharm J 245:213–215Google Scholar